Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer

医学 肺癌 化疗 程序性细胞死亡 程序性细胞死亡1 荟萃分析 肿瘤科 癌症 细胞凋亡 内科学 PD-L1 免疫疗法 生物化学 化学
作者
Hakan Bozcuk,Mehmet Artaç,Hasan Mutlu,Özlem Nuray Sever,Mustafa Yıldırım
出处
期刊:Journal of Oncology Pharmacy Practice [SAGE Publishing]
卷期号:27 (2): 405-413 被引量:3
标识
DOI:10.1177/1078155220964903
摘要

Background Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PDL-1) inhibitors have improved survival over chemotherapy in advanced Non- Small Cell Lung Cancer (NSCLC). However, it is unclear if there are class specific differences in the efficacy of Checkpoint Inhibitors (CPIs) in NSCLC, and this paper is designed to answer these clinical questions. Methods For this Meta-analysis, we searched PubMed, Science of Web, “Clinicaltrials.gov” and online sources for trials comparing PD-1 and PDL-1 CPIs in advanced NSCLC. The data for Hazard Ratio (HR) and their Confidence Intervals (CI) for Overall Survival (OS) was extracted. Results A sum of 9739 patients from 16 trials were included in the efficacy evaluation. For the OS endpoint, both PD-1 inhibitors (HR = 0.76, 95%CI = 0.69–0.83, P < 0.001) and PDL-1 inhibitors (HR = 0.84, 95%CI = 0.74–0.95, P < 0.001) were superior to chemotherapy in treatment naïve (upfront) patients, the results were similar in treatment refractory patients (PD-1 inhibitors (HR = 0.67, 95%CI = 0.60–0.75, P < 0.001) and PDL-1 inhibitors (HR = 0.78, 95%CI = 0.69–0.88, P < 0.001) were superior to chemotherapy). There was no difference in the effect of PD-1 and PDL-1 classes of CPIs over chemotherapy in treatment naïve and treatment refractory settings (Q = 1.88, df = 1, P = 0.017, and, Q = 3.27, df = 1, P = 0.070, respectively). Conclusion Efficacy of PD-1 and PDL-1 class of CPIs was not different, although differences among individual CPIs or their combinations cannot be excluded. We were also able to compute pooled efficacy data, as compared to chemotherapy alone, for trials where these groups of CPIs were utilized.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
老乡开下门吧完成签到,获得积分0
刚刚
wen发布了新的文献求助10
刚刚
1秒前
思源的应助被mer采纳,获得10
1秒前
DJY完成签到,获得积分10
1秒前
lcc完成签到,获得积分10
1秒前
科目三的应助被zhuo采纳,获得10
2秒前
sunny发布了新的文献求助10
2秒前
打打的应助被chuyangyang采纳,获得10
2秒前
2秒前
吴金伟发布了新的文献求助10
2秒前
黑黑完成签到,获得积分10
2秒前
Abstract完成签到,获得积分10
3秒前
3秒前
Glllll完成签到 ,获得积分10
3秒前
3秒前
Aen完成签到,获得积分10
3秒前
4秒前
4秒前
DJY发布了新的文献求助10
4秒前
曾经的电脑完成签到 ,获得积分10
4秒前
慧慧完成签到,获得积分10
4秒前
murphy发布了新的文献求助10
4秒前
cyr完成签到,获得积分10
4秒前
4秒前
4秒前
汉堡包的应助被科研通管家采纳,获得10
4秒前
5秒前
5秒前
NexusExplorer的应助被科研通管家采纳,获得10
5秒前
LSW发布了新的文献求助10
5秒前
Orange的应助被科研通管家采纳,获得10
5秒前
syvshc的应助被Cissie采纳,获得10
5秒前
田様的应助被科研通管家采纳,获得10
5秒前
隐形曼青的应助被科研通管家采纳,获得10
5秒前
xiaoxiao晓完成签到,获得积分10
5秒前
5秒前
NexusExplorer的应助被科研通管家采纳,获得10
5秒前
ww发布了新的文献求助10
5秒前
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170021
求助须知:如何正确求助?哪些是违规求助? 9563040
关于积分的说明 21768210
捐赠科研通 7761506
什么是DOI,文献DOI怎么找? 3430553
关于科研通互助平台的介绍 2554373
邀请新用户注册赠送积分活动 2475269